Diabetic foot treatment supported

11 April 2019

Marchmont Innovation News

Russia’s Skolkovo Foundation and Human Stem Cells Institute (HSCI), a private holding company, are supporting a young Russian company called NextGene, a Skolkovo resident. Of the $492,000 grant funding, an estimated $246,000 should come from Skolkovo and HSCI is expected to match the amount, the Skolkovo Foundation website  announced . 

The money will reportedly be used to complete phase 2 of clinical trials for NextGene’s new technology that is expected to help diabetic foot syndrome patients. 

The diabetic foot syndrome is one of the most widespread diabetes complications, responsible for 75% of nontraumatic lower extremities amputations globally. 

“Independent experts reviewed the project’s grant memo and found no analog of the new substance in the market, as well as a highly competent project team,” said Vladimir Egorov who manages the project at the Skolkovo Foundation’s Biomed Cluster.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more